Information Provided By: 
Fly News Breaks for June 3, 2019
FPRX
Jun 3, 2019 | 07:40 EDT
As previously reported, Wells Fargo analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform following review of data at ASCO for B7:H4 antibody FPA-150 in B7:H4+ patients with solid tumors including ovarian cancer. The analyst says overall response rate of 1/18 in B7:H4+ tumors was "underwhelming," with lack of clarity on dose response. Birchenough also lowered his price target on the shares to $10 from $35.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
